



Contact:

Douglas Doerfler
Chief Executive Officer
MaxCyte, Inc.
(301) 517-5556

For Immediate Release

MaxCyte to Present at the UBS Warburg Global Life Sciences Conference

Rockville, MD, October 9, 2001 -- MaxCyte today announced that it will present at the UBS Warburg Global Life Sciences Conference at 3:40 pm EDT on Friday, October 12, 2001. The conference is being held at The Pierre Hotel in New York City from October 8-12, 2001. Listen only telephone conference lines have been set up for public access to hear the presentations. For more information regarding this presentation, visit the UBS Warburg website at <http://www.ubswarburg.com>.

MaxCyte is a clinical stage biotechnology company developing targeted therapeutic products to treat severe and chronic diseases, including cancer, serious infections, cardiovascular disease and genetic disorders, based on its proprietary technology that uses blood cells for drug and non-viral gene delivery. MaxCyte is majority owned by EntreMed, Inc. For further information, please visit the MaxCyte web site at <http://www.MaxCyte.com>

EntreMed, Inc., The Angiogenesis Company(TM), (NASDAQ: ENMD) is a clinical-stage biopharmaceutical company emphasizing antiangiogenesis therapeutics that inhibit abnormal blood vessel growth associated with a broad range of diseases such as cancer, blindness and atherosclerosis. The company's strategy is to accelerate development of its core technologies through collaborations and sponsored research programs with university medical departments, research companies and government laboratories. For further information, please visit the EntreMed web site at <http://www.entremed.com>.

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

####